SCHEMBL2019229

SCHEMBL2019229

FC(F)(F)c1ccc(-c2nnc(-c3cn4c5c(cccc35)CCC4)o2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 2/20 0.46
POLB P06746 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPSR1 Q6W5P4 3/20 0.44
RAB9A P51151 3/20 0.44
BCHE P06276 2/20 0.42
ACHE P22303 2/20 0.42
BACE1 P56817 2/20 0.42
NPC1 O15118 3/20 0.42
HPGD P15428 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016725 0.89 S1PR1 (0.46) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2020602 0.88 NPC1 (0.44) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2021453 0.86 RAB9A (0.49) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2020405 0.85 NPC1 (0.43) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2019352 0.85 NPC1 (0.46) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2015858 0.85 RAB9A (0.48) KDM4ESMN1; SMN2KMT2AALDH1A1CYP1A2
SCHEMBL2015078 0.83 HTR2A (0.43) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2019393 0.83 HTR2A (0.43) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2018141 0.83 NPC1 (0.46) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL2021806 0.80 ALDH1A1 (0.44) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
WO-2011082266-A2 SUBSTITUTED HETEROCYCLIC COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 KDM4E 1439/4885SMN1; SMN2 1983/4885MEN1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.